As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...

Please provide your email address to receive an email when new articles are posted on . Patients who received cemiplimab exhibited significantly reduced risk for recurrence or death compared with ...

Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing recurrence risk by 68% in the C-POST trial. Administered post-surgery and radiation ...

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The ...

Can tattoos protect your skin from the sun's harmful rays, or do they make things worse? A new study I conducted with colleagues suggests there may be cause for concern.

Cutaneous squamous cell carcinoma (cSCC) is one of the most common types of non-melanoma skin cancer, with its incidence rising globally due to increased ultraviolet exposure, ageing populations, and ...

Please provide your email address to receive an email when new articles are posted on . The indication applies to adults with metastatic or locally advanced disease who are not candidates for curative ...

A new study from Lund University suggests people with tattoos may have a 29% higher risk of developing melanoma, a dangerous ...

The C-POST trial showed a disease-free survival benefit with adjuvant Libtayo for high-risk cutaneous squamous cell carcinoma, potentially influencing future standard care. Immunotherapy remains the ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Tattoos might seem like harmless self-expression, but could they secretly raise your skin cancer risk? A new Swedish study ...